[company_age]4.0[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]Promatix Biosciences Ltd is a data-driven company that utilizes multi-omic information to develop a robust pipeline of novel therapeutics. The company's primary focus lies in the proteome, leveraging it in conjunction with other forms of omic data to gain insights into variations between healthy and diseased states. Promatix's proprietary proteomic database, TxPro, stands as one of the largest of its kind, encompassing thousands of primary tissue samples sourced and analyzed from both healthy and diseased individuals. This database serves as a foundation for the discovery and validation of novel drug targets through differential protein expression and presentation analysis across diseased and normal tissue. Promatix's team meticulously selects the most promising drug targets in silico to develop treatments for cancer. The company's unique approach to drug development sets it apart from competitors, as it focuses on the proteome, which is often overlooked in traditional drug discovery processes. This focus on the proteome allows Promatix to identify and validate novel drug targets that have the potential to transform the treatment of cancer.[/description][ps]Novel therapeutics for cancer treatment[/ps]